It is mainly used for primary liver cancer treatment. NCTD could increase white blood cells, protecting liver cells and regulating immunity. It is the first new drug developed in my country to treat liver cancer and hepatitis. Norcantharidin (NCTD) is a derivative of cantharidin. The exploration to drug carriers of high molecular material is becoming a hot research topic at present. With the intention of improving the selectivity of the drugs and minimizing their toxicity, further research and development with biocompatibility and biodegradability were performed to attain the purpose of slow drug release, which would not only fortify the effect of drug targeting but also enable the drug treatment to achieve synergy and detoxification. Conventional preparations are short in their half-life and bioavailability, so only a small amount of drug reaches the tumor site, increasing the dose of the drug but also increasing the toxic and side effects. Moreover, the survival rate of liver cancer in China is the worst. Nowadays, liver cancer has ranked the sixth cancer death worldwide. Cancer is one of the primarily death causes around the world. The high morbidity of malignancies is severely jeopardizing public health in recent year. Tail vein injection of NCTD-NLC has the best drug delivery effect.
In conclusion, the NCTD-NLC prepared in this study had a mighty inhibitory effect towards HepG2 cellular viability and an accelerating work on apoptosis. Through the tumorigenesis test to nude mice, we found that the tumor inhibition rate of the NCTD-NLC tail vein injection group had a 27.48% elevation in contrast to the NCTD gavage group, and it was also the group with the best tumor inhibition efficiency. On the basis of the data we obtained, we found that the group with NCTD-NLC tail vein injection had an obvious advantage in drug delivery when compared with other groups. The apoptosis rate was positively correlated with the concentration of NCTD-NLC.
Along with the concentration increasing, significantly increasing cellular apoptosis and gradually decreasing cellular viability were observed. Cell viability was negatively correlated with NCTD-NLC concentration. Then, our outcomes showed that NCTD-NLC had a notable inhibitory effect on HepG2 cells, leading to a gradually decreased cellular viability. Six hours after the administration, we performed the High Performance Liquid Chromatography (HPLC) detection to estimate the NCTD content in the heart, liver, spleen, lung, kidney and plasma of rats. In this study, we exploited our experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cells cultured in vitro were given with NCTD-NLC administration then, the estimation on cellular proliferation and apoptosis was accomplished through MTT and flow cytometry. Development for new antitumor drugs and the exploration to drug carriers are becoming the concerned focus. Malignant tumors have become the main cause of harm to human life and health.
0 kommentar(er)
